Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon
Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22. Once the company’s coming financing need is sorted, and the positive progress of NEX-20 and NEX-22 continues, we see the potential for a positive share momentum in the coming 12–18 months. Given the initial pharmacokinetic data from the clinical phase I trial with NEX-20, we nudge our base case to SEK6.4 (6.1).
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/